AU2019211382B2 - Aminopyrrolotriazines as kinase inhibitors - Google Patents

Aminopyrrolotriazines as kinase inhibitors Download PDF

Info

Publication number
AU2019211382B2
AU2019211382B2 AU2019211382A AU2019211382A AU2019211382B2 AU 2019211382 B2 AU2019211382 B2 AU 2019211382B2 AU 2019211382 A AU2019211382 A AU 2019211382A AU 2019211382 A AU2019211382 A AU 2019211382A AU 2019211382 B2 AU2019211382 B2 AU 2019211382B2
Authority
AU
Australia
Prior art keywords
triazin
amino
pyrrolo
trifluoromethyl
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2019211382A
Other languages
English (en)
Other versions
AU2019211382A1 (en
Inventor
Murugaiah ANDAPPAN MURUGAIAH SUBBAIAH
Jie Chen
Carolyn Diane Dzierba
Hua Gong
Jason M. Guernon
Junqing Guo
Amy C. HART
Guanglin Luo
John E. Macor
William J. Pitts
Jianliang Shi
Sing-Yuen Sit
Brian Lee Venables
Scott Hunter Watterson
Carolyn A. WEIGELT
Yong-Jin Wu
Zhizhen Barbara Zheng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AU2019211382A1 publication Critical patent/AU2019211382A1/en
Application granted granted Critical
Publication of AU2019211382B2 publication Critical patent/AU2019211382B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2019211382A 2018-01-26 2019-01-24 Aminopyrrolotriazines as kinase inhibitors Ceased AU2019211382B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862622415P 2018-01-26 2018-01-26
US62/622,415 2018-01-26
PCT/US2019/014918 WO2019147782A1 (en) 2018-01-26 2019-01-24 Aminopyrrolotriazines as kinase inhibitors

Publications (2)

Publication Number Publication Date
AU2019211382A1 AU2019211382A1 (en) 2020-09-17
AU2019211382B2 true AU2019211382B2 (en) 2022-06-16

Family

ID=65363405

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019211382A Ceased AU2019211382B2 (en) 2018-01-26 2019-01-24 Aminopyrrolotriazines as kinase inhibitors

Country Status (16)

Country Link
US (1) US11618753B2 (https=)
EP (1) EP3743430B1 (https=)
JP (1) JP7307734B2 (https=)
KR (1) KR102759231B1 (https=)
CN (1) CN112262139B (https=)
AR (1) AR114186A1 (https=)
AU (1) AU2019211382B2 (https=)
BR (1) BR112020014516A2 (https=)
CA (1) CA3088548A1 (https=)
EA (1) EA202091777A1 (https=)
ES (1) ES2959399T3 (https=)
IL (1) IL276269A (https=)
MX (1) MX2020007531A (https=)
SG (1) SG11202007035YA (https=)
TW (1) TW201940485A (https=)
WO (1) WO2019147782A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3580220B1 (en) 2017-02-13 2021-11-17 Bristol-Myers Squibb Company Aminotriazolopyridines as kinase inhibitors
DK3704118T3 (da) 2017-10-30 2022-03-14 Bristol Myers Squibb Co Aminoimidazopyrazin som kinasehæmmere
EP3849969B1 (en) 2018-09-13 2023-04-19 Bristol-Myers Squibb Company Indazole carboxamides as kinase inhibitors
EP3849968B1 (en) 2018-09-13 2022-12-21 Bristol-Myers Squibb Company 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1)
WO2021067654A1 (en) 2019-10-03 2021-04-08 Bristol-Myers Squibb Company Indazole carboxamides as kinase inhibitors
KR20220139947A (ko) * 2020-02-07 2022-10-17 샌트랄 글래스 컴퍼니 리미티드 경화성 조성물, 경화물, 전자 디바이스, 표시 장치, 광학 부재, 중합체, 감광성 조성물, 패턴 및 화합물
WO2022007921A1 (zh) * 2020-07-10 2022-01-13 北京范恩柯尔生物科技有限公司 三嗪类化合物及其组合物和用途
CN111925345B (zh) * 2020-08-21 2023-09-29 上海科利生物医药有限公司 一种手性2-氨甲基四氢呋喃的制备方法
AR123793A1 (es) 2020-10-19 2023-01-11 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de quinasas
CN116745361A (zh) * 2021-02-10 2023-09-12 中央硝子株式会社 树脂组合物、树脂膜、基材、聚合物以及聚合性单体
CN113563214B (zh) * 2021-07-06 2024-02-02 山东鲁泰控股集团有限公司石墨烯高分子复合材料研发中心 一种氨基乙酸的合成方法
CN113527220A (zh) * 2021-07-26 2021-10-22 京博农化科技有限公司 一种脱硫丙硫菌唑异构体的合成方法
CN114989079B (zh) * 2022-06-21 2023-06-23 中国药科大学 Ripk1激酶靶点抑制剂及其医药用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009046448A1 (en) * 2007-10-04 2009-04-09 Intellikine, Inc. Chemical entities and therapeutic uses thereof
WO2011123493A1 (en) * 2010-03-31 2011-10-06 Bristol-Myers Squibb Company Substituted pyrrolotriazines as protein kinase inhibitors
WO2016064958A1 (en) * 2014-10-22 2016-04-28 Bristol-Myers Squibb Company Heteroaryl substituted pyrrolotriazine amine compounds as pi3k inhibitors
WO2016064957A1 (en) * 2014-10-22 2016-04-28 Bristol-Myers Squibb Company Bicyclic heteroaryl amine compounds as pi3k inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5116687B2 (ja) 2005-11-02 2013-01-09 バイエル・ファルマ・アクチェンゲゼルシャフト がんおよび他の過剰増殖性疾患の処置のためのピロロ［２，１−ｆ］［１，２，４］トリアジン−４−イルアミンＩＧＦ−１Ｒキナーゼ阻害剤
ES2365869T3 (es) * 2005-11-17 2011-10-11 OSI Pharmaceuticals, LLC COMPUESTOS BICÍCLICOS FUSIONADOS INHIBIDORES DE LA mTOR.
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
WO2007064931A2 (en) 2005-12-02 2007-06-07 Bayer Healthcare Llc Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
US8765754B2 (en) 2009-04-29 2014-07-01 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
TW201107329A (en) * 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
IL266563B (en) 2009-10-06 2022-09-01 Millennium Pharm Inc Heterocyclic compounds useful as pdk1 inhibitors
US9783573B2 (en) 2012-09-18 2017-10-10 Bristol-Myers Squibb Company IAP antagonists
EP3054955B1 (en) 2013-10-11 2018-05-30 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
KR102483020B1 (ko) 2016-03-28 2023-01-04 인사이트 코포레이션 Tam 저해제로서의 피롤로트리아진 화합물
WO2018017435A1 (en) 2016-07-22 2018-01-25 Accro Bioscience Inc. Heteroaryl compounds as inhibitors of necrosis, composition and application thereof
EP3580220B1 (en) 2017-02-13 2021-11-17 Bristol-Myers Squibb Company Aminotriazolopyridines as kinase inhibitors
DK3704118T3 (da) 2017-10-30 2022-03-14 Bristol Myers Squibb Co Aminoimidazopyrazin som kinasehæmmere
EP3849968B1 (en) 2018-09-13 2022-12-21 Bristol-Myers Squibb Company 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1)
EP3849969B1 (en) 2018-09-13 2023-04-19 Bristol-Myers Squibb Company Indazole carboxamides as kinase inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009046448A1 (en) * 2007-10-04 2009-04-09 Intellikine, Inc. Chemical entities and therapeutic uses thereof
WO2011123493A1 (en) * 2010-03-31 2011-10-06 Bristol-Myers Squibb Company Substituted pyrrolotriazines as protein kinase inhibitors
WO2016064958A1 (en) * 2014-10-22 2016-04-28 Bristol-Myers Squibb Company Heteroaryl substituted pyrrolotriazine amine compounds as pi3k inhibitors
WO2016064957A1 (en) * 2014-10-22 2016-04-28 Bristol-Myers Squibb Company Bicyclic heteroaryl amine compounds as pi3k inhibitors

Also Published As

Publication number Publication date
EA202091777A1 (ru) 2020-10-14
TW201940485A (zh) 2019-10-16
KR20200115550A (ko) 2020-10-07
CA3088548A1 (en) 2019-08-01
ES2959399T3 (es) 2024-02-26
IL276269A (en) 2020-09-30
MX2020007531A (es) 2020-09-09
JP7307734B2 (ja) 2023-07-12
BR112020014516A2 (pt) 2020-12-08
SG11202007035YA (en) 2020-08-28
EP3743430B1 (en) 2023-08-02
KR102759231B1 (ko) 2025-01-22
CN112262139B (zh) 2023-07-25
US20200347071A1 (en) 2020-11-05
EP3743430A1 (en) 2020-12-02
US11618753B2 (en) 2023-04-04
WO2019147782A1 (en) 2019-08-01
AR114186A1 (es) 2020-07-29
CN112262139A (zh) 2021-01-22
AU2019211382A1 (en) 2020-09-17
JP2021511363A (ja) 2021-05-06

Similar Documents

Publication Publication Date Title
AU2019211382B2 (en) Aminopyrrolotriazines as kinase inhibitors
AU2018217488B2 (en) Aminotriazolopyridines as kinase inhibitors
EP3704118B1 (en) Aminoimidazopyridazines as kinase inhibitors
CN104254533B (zh) 用作激酶抑制剂的噻唑或噻二唑取代的吡啶基化合物
CN104159896B (zh) 用作激酶抑制剂的杂环取代的吡啶基化合物
EP3849968B1 (en) 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1)
EA042342B1 (ru) Аминопирролотриазины в качестве ингибиторов киназы
EA042124B1 (ru) Аминоимидазопиридазины в качестве ингибиторов киназ

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired